Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Advertisement

One-time CRISPR therapy lonvo-z shows durable attack control in hereditary angioedema – Intellia

Written by | 22 Nov 2026 | Allergy & Immunology

Intellia Therapeutics has presented new clinical and patient-reported data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE). The data came from seven presentations at the ACAAI 2026 Annual Scientific Meeting.

Lonvo-z is an investigational in vivo CRISPR/Cas9 gene-editing therapy. A single dose, given in an outpatient setting, inactivates the KLKB1 gene to permanently lower plasma kallikrein.

Four-year durability

In the Phase 1/2 study, all patients had deep and durable reductions in plasma kallikrein. The mean reduction was 84% at four weeks and was maintained for up to four years. No new long-term risks were identified.

After a one-time 50 mg dose (n=32), at least 90% of patients were attack-free in each month after the first year, with up to four years of follow-up.

Phase 3 HAELO

HAELO included 35 patients who were taking long-term prophylaxis (LTP) when they entered the study and were randomised to lonvo-z. In these patients, the mean HAE attack rate fell by 81% compared with their rate on prior LTP, and 63% achieved complete control. Benefit was consistent across all prespecified subgroups, whatever the disease severity or prior LTP.

HAELO also met its key secondary endpoint on quality of life. Angioedema Quality of Life (AE-QoL) total score fell by 23.5 points with lonvo-z, compared with 6.5 points with placebo. A 6-point reduction is the threshold for a clinically important difference.

Integrated analysis

An integrated analysis covered 93 patients who received a single 50 mg dose across Phase 1/2 and HAELO. Attacks fell by 89% overall from baseline through up to four years. 97% of patients never started LTP after treatment, and all were LTP-free at their latest follow-up.

The most common adverse events (in more than 15% of patients) were infusion-related reactions, headache, fatigue and nasopharyngitis.

Patient experience

Interviews were held with 23 Phase 1/2 patients. All of them described their HAE as well controlled after lonvo-z, compared with 48% before treatment. 22 (96%) described lonvo-z as an optimal therapy.

The FDA has accepted the Biologics License Application for lonvo-z with Priority Review. The PDUFA target action date is 10 March 2027.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.